Related Experiment Video

Updated: May 1, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

[Clinical usefulness of biomarkers in cardiac failure]

Alejandro Paredes C, Julián Vega, Ana de León

    Revista Medica De Chile
    |April 15, 2014
    PubMed

    Insights

    Diagnosing cardiac failure early requires careful assessment. Brain natriuretic peptide is valuable, but combining markers improves risk stratification and understanding of heart failure.

    Area of Science:

    • Biomarkers in cardiovascular medicine
    • Physiopathology of heart failure
    • Clinical diagnostics

    Context:

    • Early and precise diagnosis of cardiac failure is crucial.
    • Natriuretic peptides are clinically useful biomarkers.
    • Brain natriuretic peptide offers diagnostic and prognostic value.

    Purpose:

    • To explore the role of natriuretic peptides in cardiac failure assessment.
    • To highlight the importance of considering confounders for Brain natriuretic peptide interpretation.
    • To emphasize the benefits of combining multiple markers for improved risk stratification.

    Summary:

    • Natriuretic peptides, particularly Brain natriuretic peptide, are key in diagnosing and assessing cardiac failure risk.
    • Clinical interpretation requires awareness of potential confounders affecting Brain natriuretic peptide levels.
    • Combining various biomarkers enhances risk stratification and compensates for individual marker limitations.

    Impact:

    • Improved diagnostic accuracy and risk stratification for cardiac failure patients.
    • Potential for new therapeutic strategies based on a deeper understanding of cardiac failure pathophysiology.
    • Enhanced clinical decision-making through comprehensive biomarker analysis.

    More Related Videos

    A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

    A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

    Published on: August 8, 2013

    16.1K

    Related Concept Videos

    Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

    Blood Studies for Cardiovascular System I: Cardiac Biomarkers

    Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
    The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
    Troponins
    Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
    1.2K
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    765
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.9K
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    790
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    2.7K
    Acute Coronary Syndrome III: Diagnostic Studies01:30

    Acute Coronary Syndrome III: Diagnostic Studies

    Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
    495